JPMorgan initiated coverage of BillionToOne (BLLN) with an Overweight rating and $150 price target BillionToOne is a molecular diagnostics company that leverages proprietary single molecule next-generation sequencing technology used in prenatal and oncology testing, the analyst tells investors in a research note. The firm likes the setup for the stock, saying the company will continue to build out its commercial infrastructure to capture growing demand in both prenatal and oncology.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLLN:
- BillionToOne initiated with a Hold at Jefferies
- BillionToOne, Inc.: Strong Market Position and Profitability Justify Buy Rating
- BillionToOne’s Innovative Platform Poised for Growth in Reproductive Health and Oncology Markets
- BillionToOne’s Innovative Sequencing Platform and Strong Growth Prospects Justify Buy Rating and $150 Price Target
- Balanced Outlook on BillionToOne, Inc.: High Growth Potential Amidst Competitive Challenges